Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Brain Tumor Adult Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)

NCT07224347
View directory record Official record
Conditions
Functional Disability, Dementia, Heart Disease, Stroke, Cancer, Bleeding, Depression, Frailty
Interventions
Not listed
Lead sponsor
Anne Murray
Other
Eligibility
65 Years and older
Enrollment
19,114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jul 22, 2026, 7:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

New Approach to Objectively Measure Social Engagement in Older Adults With Hearing Loss

NCT06781749
View directory record Official record
Conditions
Hearing Loss, Bilateral (Causes Other Than Tumors)
Interventions
Hearing aid use
Device
Lead sponsor
University of Southern California
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 22, 2026, 7:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin

NCT00423852
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, ifosfamide, paclitaxel, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Jul 22, 2026, 7:05 AM EDT
Completed No phase listed Observational

Exploring Compensation to Maintain Cognitive Function in Adults Newly Diagnosed With Brain Cancer

NCT04075370
View directory record Official record
Conditions
Primary Brain Tumor, Brain Metastases, Adult
Interventions
Neuropsychological Testing
Other
Lead sponsor
Duke University
Other
Eligibility
30 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Jul 22, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

NCT01817751
View directory record Official record
Conditions
Glioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma, WHO Grade III Glioma
Interventions
sorafenib tosylate, valproic acid, sildenafil citrate
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Jul 22, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

NCT00112502
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Glioblastoma Multiforme
Interventions
Celecoxib, Isotretinoin, Temozolomide, Thalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
12
States / cities
Fort Smith, Arkansas • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2021 · Synced Jul 22, 2026, 7:05 AM EDT
Not listed Phase 2 Interventional

131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma

NCT00114309
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma, Oligo-Astrocytoma, Gliosarcoma
Interventions
131-I-TM-601, 131I-TM601
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2009 · Synced Jul 22, 2026, 7:05 AM EDT
Completed Phase 2 Interventional

Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors

NCT00541138
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, tamoxifen citrate, topotecan hydrochloride, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Jul 22, 2026, 7:05 AM EDT
Withdrawn Phase 2 Interventional

NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

NCT02348255
View directory record Official record
Conditions
Adult Brain Glioblastoma, Recurrent Adult Brain Neoplasm
Interventions
Electric Field Therapy, Bevacizumab, Carmustine, Quality-of-Life Assessment
Procedure · Biological · Drug + 1 more
Lead sponsor
University of California, Davis
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Sacramento, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Jul 22, 2026, 7:05 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)

NCT01110876
View directory record Official record
Conditions
Brain Cancer, Glioblastoma Multiforme
Interventions
Vorinostat, Erlotinib, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Jul 22, 2026, 7:05 AM EDT
Terminated Not applicable Interventional Results available

MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma

NCT00756106
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, Imaging biomarker analysis, Photon Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Jul 22, 2026, 7:05 AM EDT
Not listed Phase 2 Interventional

Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT00004204
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
10
States / cities
Stanford, California • Miami Beach, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Jul 22, 2026, 7:05 AM EDT
Recruiting Phase 1 Interventional

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

NCT04689048
View directory record Official record
Conditions
Brain Metastases, Adult, Brain Metastases, Brain Cancer
Interventions
18F fluciclovine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 7:05 AM EDT
Completed Phase 3 Interventional

SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme

NCT00003293
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
leflunomide, procarbazine hydrochloride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Jul 22, 2026, 7:05 AM EDT
Terminated Phase 1 Interventional

S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer

NCT00023634
View directory record Official record
Conditions
Brain Tumors, Gastric Cancer, Ovarian Cancer, Prostate Cancer
Interventions
KLH, GMCSF
Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
13
States / cities
Bay City, Michigan • Port Huron, Michigan • Bellingham, Washington + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jul 22, 2026, 7:05 AM EDT
Completed Phase 2 Interventional

Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma

NCT00003467
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, polifeprosan 20 with carmustine implant, surgical procedure
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Jul 22, 2026, 7:05 AM EDT
Completed Phase 1 Interventional

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

NCT00544284
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, temozolomide, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Jul 22, 2026, 7:05 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer

NCT00003309
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, cisplatin, cyclophosphamide, etoposide, vincristine sulfate, adjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
14
States / cities
Tampa, Florida • Chicago, Illinois • Urbana, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 22, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional Results available

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

NCT01966809
View directory record Official record
Conditions
Brain Tumor, Recurrent
Interventions
Photofrin photodynamic therapy.
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Jul 22, 2026, 7:05 AM EDT
Active, not recruiting Phase 3 Interventional

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

NCT00978458
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neurotoxicity
Interventions
temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
168
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 22, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers

NCT03538587
View directory record Official record
Conditions
Glioblastomas, Sarcoma, Astrocytoma, Brain Cancer, Leukemia
Interventions
Enhanced Mindfulness Intervention, Psychoeducation
Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 24 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 22, 2026, 7:05 AM EDT
Completed Phase 1 Interventional

Karenitecin in Treating Patients With Recurrent Malignant Glioma

NCT00014521
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
karenitecin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2008 · Synced Jul 22, 2026, 7:05 AM EDT
Completed Phase 1Phase 2 Interventional

ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma

NCT00352313
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
ATN-161, carboplatin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Jul 22, 2026, 7:05 AM EDT
Terminated Phase 1 Interventional

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

NCT00003926
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions
amifostine trihydrate, busulfan, filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation (PBSC)
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Year to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Jul 22, 2026, 7:05 AM EDT